

**ACTION:** Notice; reopening of comment period.

**SUMMARY:** The Food and Drug Administration (FDA) is reopening until November 6, 2009, the comment period for the notice of public meeting and request for comments that appeared in the **Federal Register** of June 3, 2009 (74 FR 26712). In the notice of public meeting and request for comments, FDA's Transparency Task Force requested comments on ways in which FDA can make useful and understandable information about FDA activities and decision making more readily available to the public. The agency is taking this action because the agency is planning a second public meeting this fall and is reopening the comment period to allow interested persons additional time to submit comments.

**DATES:** Submit written or electronic comments by November 6, 2009.

**ADDRESSES:** Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.regulations.gov>. All such comments should be identified with the docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** Afia Asamoah, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, rm. 2208, Silver Spring, MD 20993, 301-796-4625, FAX: 301-847-3531, e-mail: [Afia.Asamoah@fda.hhs.gov](mailto:Afia.Asamoah@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of June 3, 2009 (74 FR 26712), FDA published a notice of public meeting and request for comments on ways in which FDA can make useful and understandable information about FDA activities and decisionmaking more readily available to the public, in a manner compatible with the agency's goal of protecting confidential information, as appropriate. Interested persons were given until August 7, 2009, to submit comments. The agency is planning to hold a second meeting in the fall of 2009 about these issues and is reopening the comment period until November 6, 2009. FDA has also established an online blog at <http://fdatransparencyblog.fda.gov> in which interested persons may provide feedback on specific topics. The blog is expected to run through November 2009.

Interested persons may submit written or electronic comments to the Division of Dockets Management (see

**ADDRESSES**). Submit a single copy of electronic comments to <http://www.regulations.gov> or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Dated: August 12, 2009.

**Jeffrey Shuren,**

*Associate Commissioner for Policy and Planning.*

[FR Doc. E9-19778 Filed 8-17-09; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Board of Scientific Counselors, National Center for Public Health Informatics (BSC, NCPHI)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

*Time and Date:* 8:30 a.m.-5 p.m., September 2, 2009.

*Place:* Hyatt Regency, 265 Peachtree Street NE., Atlanta, Georgia, 30303 *Tel:* (404) 577-1234, *Fax:* (404) 588-4137.

#### Maps & Directions

*This meeting will also be teleconferenced:* Toll Free Number: (866) 713-5586, Participant's pass code 4624038.

*Status:* Open to the public, limited only by the space available.

*Purpose:* The committee shall advise the Secretary, HHS, and the Director, CDC, concerning strategies and goals for the programs and research within the national centers; shall conduct peer-review of scientific programs; and monitor the overall strategic direction and focus of the national centers. The board, after conducting its periodic reviews, shall submit a written description of the results of the review and its recommendations to the Director, CDC. The board shall perform second-level peer review of applications for grants-in-aid for research and research training activities, cooperative agreements, and research contract proposals relating to the broad areas within the national center.

*Matters to be Discussed:* The board will discuss BSC, NCPHI-related

matters, including an update on NCPHI Programs and other BSC-related activities.

Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Dr. Scott McNabb, National Center for Public Health Informatics, CDC, 1600 Clifton Road, NE., Mailstop E-78, Atlanta, Georgia 30333, Telephone (404) 498-6427, Fax (404) 498-6235.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and the Agency for Toxic Substance and Disease Registry.

Dated: August 10, 2009.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E9-19754 Filed 8-17-09; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of General Medical Sciences; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory General Medical Sciences Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory General Medical Sciences Council.

*Date:* September 10-11, 2009.

*Closed:* September 10, 2009, 8:30 a.m. to 5 p.m.